Neuronal nicotinic acetylcholine receptor subunit (nAChR subunit)

Neuronal nicotinic acetylcholine receptor subunits are integral membrane proteins that co-assemble as pentamers to form functional nAChRs, allowing rapid, excitatory neurotransmission in the central and peripheral nervous systems. There are at least seventeen neuronal nAChR subunit genes identified in mammals—including ten α subunits (α2–α10), four β subunits (β2–β4), and others such as δ, γ, and ε. Functional neuronal nAChRs are typically either homopentamers (e.g., α7) or heteropentamers (e.g., α4β2, α6β4) whose composition confers distinct pharmacological and physiological properties. These receptors are essential for cognition, memory, pain processing, neuroprotection, and inflammation and are implicated in multiple disorders including Alzheimer’s disease, schizophrenia, addiction, and inflammatory conditions. nAChR subunits contain characteristic structural motifs such as an extracellular ligand-binding domain, four transmembrane domains, and a signature Cys-loop. A wide variety of clinically relevant and experimental drugs target these receptors through mechanisms including direct agonism, antagonism, or allosteric modulation. Because "neuronal acetylcholine receptor subunits" covers all possible neuronal nAChR subunit proteins rather than a single defined molecular target, the entry is considered overly broad for therapeutic targeting. For a more precise therapeutic or research target, specify the particular subunit or mature receptor subtype (e.g., α7 nAChR, α4β2 nAChR) since these mediate specific biological and disease processes and are the focus of most drug development efforts.

Other names

Neuronal nicotinic receptor subunitnAChR subunitneuronal cholinergic receptor subunit

Agonism (activation by direct binding) Antagonism (competitive blockade) Positive allosteric modulation (enhancing receptor function by binding to non-orthosteric sites) Negative allosteric modulation (inhibition by binding distinct sites) Indirect modulation via neurotransmitter release